Praxis Precision Medicines, Inc. (PRAX)

In October 2025, Praxis reported positive topline Phase 3 results for ulixacaltamide, leading to a significant stock increase. In December 2025, the FDA granted Breakthrough Therapy Designation for ulixacaltamide, further contributing to a stock price increase. Also in December 2025, Praxis announced positive results from the EMBOLD study for relutrigine, resulting in a stock price surge. In January 2026, Praxis announced the pricing of a $575 million public offering. Overall, the share price of PRAX has seen a substantial increase, reaching an all-time high on December 29, 2025.

As a clinical-stage biopharmaceutical company without commercialized products, Praxis Precision Medicines, Inc. does not currently have discernible demand seasonality for its products or services.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders characterized by a neuronal excitation-inhibition imbalance, operating within the biotechnology and pharmaceutical industry. The company utilizes two proprietary platforms: Cerebrum and Solidus, and its major product candidates include Ulixacaltamide, Vormatrigine, Relutrigine, PRAX-020, Elsunersen, PRAX-080, PRAX-090, and PRAX-100, which are in various stages of clinical development.

Praxis Precision Medicines, Inc. is headquartered in Boston, Massachusetts, United States.

Praxis Precision Medicines, Inc. has generally maintained a positive brand reputation, driven by promising clinical trial results and regulatory milestones. The company has a consensus rating of "Moderate Buy" from brokerages, with an average 12-month price target of $436.67. Key events positively affecting its reputation include positive Phase 3 results for ulixacaltamide, the FDA granting Breakthrough Therapy Designation for ulixacaltamide, and positive results from the EMBOLD study for relutrigine. There is no readily available information indicating specific events that have negatively affected the company's brand reputation in the past year.

Praxis Precision Medicines, Inc. has a diverse ownership structure, with institutional shareholders holding approximately 98.64% of the stock, insiders owning about 56.08%, and retail investors holding 0.00%. Major institutional owners include Janus Henderson Group Plc, Adage Capital Partners Gp, L.l.c., and BlackRock, Inc. Bsof Parallel Master Fund LP is the largest individual shareholder. Insiders have sold more company stock than they have bought in the past three months.